Prolonged fosaprepitant administration for prevention of cisplatin-induced nausea and vomiting in lung cancer

Phase 4, randomised, open-label trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV) and bronchial carcinoma (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Complete response rate of chemotherapy-induced nausea and vomiting, Fully protected days for chemotherapy-induced nausea and vomiting and 6 more. Started Feb 2021; status: recruiting.